GenVec News

GenVec, Inc. appointed Cynthia Collins President and Chief Executive Officer, andis expected to be appointed to the Board of Directors of GenVec.

GAITHERSBURG, Md., May 25, 2012 /PRNewswire/ -- GenVec, Inc. announced today that on May 23, 2012 it granted an option to purchase shares of its common stock to Cynthia Collins, its newly appointed President and Chief Executive Officer.

GenVec, Inc. announced today that on May 23, 2012 it granted an option to purchase shares of its common stock to Cynthia Collins, its newly appointed President and Chief Executive Officer.

GAITHERSBURG, Md., May 21, 2012 /PRNewswire/ -- GenVec, Inc. today announced that effective May 23, 2012 Cynthia Collins has been appointed as President and Chief Executive Officer.

GenVec extended its Research Collaboration and License Agreement with Novartis. Under the extension, Novartis will fund research at GenVec through Encouraging preclinical proof of concept data generated in non-human primates involving GenVec's respiratory syncytial virus vaccine program were presented at Keystone Symposia's 2012 Meeting on Viral ... (more)

Gaithersburg-based GenVec Inc. posted a wider loss in its latest quarter as cost reductions failed to make up for a drop in revenue.

GenVec, Inc. announced today that it has received a Phase I Small Business Innovation and Research grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health to support the Company's Respiratory Syncytial Virus vaccine program.

GAITHERSBURG, Md., May 3, 2012 /PRNewswire/ -- GenVec, Inc. will report financial results for the first quarter ended March 31, 2012 on Thursday, May 10, 2012, before the U.S. financial markets open.